A Agilent Technologies Inc.

Agilent Technologies Presents Early Career Professor Award to Dr. Roeland Verhaak

Agilent Technologies Inc. (NYSE: A) has named Roeland G.W. Verhaak, Ph.D., as the winner of the company’s prestigious Early Career Professor Award.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161018005055/en/

Agilent award winner Dr. Verhaak (Photo: Business Wire)

Agilent award winner Dr. Verhaak (Photo: Business Wire)

Dr. Verhaak has been selected for his contributions to the implementation of transcriptomics, genomics, and big-data analysis to the classification and diagnosis of various cancer types, including acute myeloid leukemia and glioblastoma. His approach and results spearheaded the implementation of the molecular analysis of cancer.

Dr. Verhaak recently joined The Jackson Laboratory (JAX) as professor and associate director of computational biology.

“Dr. Verhaak is recognized internationally for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches. His data-driven, unbiased analyses of cancer genomics and profound understanding of cancer biology are improving our ability to identify clinically relevant subtypes of cancer,” said Jack Wenstrand, Agilent's director of university relations and external research. "Agilent is pleased to recognize Dr. Verhaak with this award and to support his important research at JAX."

“We’re so pleased that Dr. Verhaak has received this prestigious award in recognition of his outstanding work in advancing human health,” said Charles Lee, Ph.D., FACMG, scientific director and professor at JAX Genomic Medicine.

The annual Agilent Early Career Professor Award was established in 2008. Through this award, Agilent seeks to recognize the achievements of academic researchers in the early stages of their careers and to establish strong collaborative relationships with them early in their professional lives. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

EN
18/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch